Monday, May 17, 2010

NNVC - functional cure for HIV/AIDS

The lineup of prestigious research partners continues, an affirmation of the underlying science and ultimately, a much, much higher market cap.  See also the sentence I highlighted in bold.


NanoViricides Signs anti-HIV Drug Candidate Testing Agreement with University of California, San Francisco
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that it has signed a Research Agreement with the University of California, San Francisco (UCSF) for testing of its anti-HIV drug candidates. Cheryl Stoddart, PhD, Assistant Professor in the UCSF Division of Experimental Medicine, will be the Principal Investigator.

Dr. Stoddart is a recognized investigator in preclinical studies of anti-HIV compounds using the standard SCID-hu Thy/Liv humanized mouse model. In particular, she is well known for her work in validating that this mouse model is capable of accurately predicting clinical antiviral efficacy in humans. The National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), has recognized UCSF as an important site for anti-HIV drug screening studies.

Dr. Stoddart’s in-vivo testing of anti-HIV nanoviricides will complement the Company’s previously announced in-vitro anti-HIV testing that is currently underway at the Southern Research Institute in Frederick, MD.

The Company has previously performed anti-HIV nanoviricides testing in vivo at KARD Scientific, Beverly, MA. In these studies, several nanoviricide drug candidates were shown to have equal effectiveness in terms of multiple parameters to a clinical anti-HIV HAART three-drug cocktail. The HAART cocktail drugs were administered at a much greater total dosage (4,100 mg/kg of HAART) than the nanoviricides (only 150mg/kg of the nanoviricides). This study evaluated several parameters including the reduction of HIV viral load, improvement in CD4+/CD8+ double-positive human T cells, and HIV particle count inside human T cells in the transplant, among others. The best nanoviricide drug candidate was greater than 25X (2,500%) superior to the HAART drug cocktail based on the amount of drug that produced comparable or superior effect. If these results are indicative of clinical response in humans, the Company believes that HIVCide™, its lead drug candidate against HIV, may constitute a “functional cure” for HIV/AIDS, either by itself, or in combination with existing therapies.

“We are very interested to find out how our prior results compare to the standardized studies in Dr. Stoddart’s lab,” said Anil R. Diwan, PhD, President of the Company.


Anonymous said...

The 'functional cure for HIV/AIDS' has been used in many previous PRs. what is need is some actual results.

These PRs are not what the market is looking for and the price will never hold $2.00 unless something more comes soon.

Anonymous said...

They will after taking yr shares

A said...

I maintain my pretty damn aggressive forecast of a triple digit share price by 2014. Each step of the development ladder is thus evaluated, in my mind, on whether it is consistent with that forecast.

Without a doubt, in-vivo testing of anti-HIV nanoviricides by Dr. Stoddart's lab is consistent with the paradigm changing medical breakthrough of our lifetimes. Once these results are published, the stock should be a healthy multiple of current pricing.

pimaCanyon said...

is this article a recent announcement? If so, it's strange that NNVC is down today. The good news, however, is that MMRF is up!

tapped out said...

Sell the news mentality is the order of the day!

Anonymous said...

Allan, rather tired of NNVC and their endless testing. Occasionally they release results (from a minority of tests, it seems).

Each time we hear "this is the test that will make the stock skyrocket", and it never does. And as more shares hit the market, it seems increasingly unlikely that it ever will.

They need to show the world they are serious about developing a drug and file a drug application already. No applications = no drugs.

Anonymous said...

Anyone, Re: NNVC

Is this normal? A Company that has so many Universities interested, testing taking place, positive news coming out and still today lose in the market?

I am perplexed.

Anonymous said...

Looks like there is support for NNVC at $1.70.

I agree with Allan's prospect for this company, however the volatility is high.Got out at $2.30.

We'll get back in at support if it holds. Trading this stock is best for me as I can not tolerate a 25%+


Anonymous said...

allen,your call on vxx is awesome,it's still a buy? or wait for dip?thanks,you r a real guru.

mathoa said...

allen your call on vxx is awesome,it's still a buy now?or wait for a deep?thanks,my guru!

apostleshadamishe said...


is being proven by the more than 400 individuals who have taken a dose of 60 ml three times daily for 21 days. The result is that AMBUSH 'KILLS' the virus by causing the protein envelope to rupture and the viral particles are discarded by the white blood cells. AMBUSH is able to 'KILL' the virus that are 'hiding' in the lymph system by its 'natural radioactive' properties. This process allows the body to 'return to normal health' with a corresponding immunity to that or those strains of the virus.

What is AMBUSH ?
AMBUSH is a radioactive isotope of uranium that is found in the 'palm' plant of which there are more than 3000 species. When ingested, AMBUSH causes the body temperature in the trunk area to rise to about 102 degrees when the individual is sleeping. The preparation takes four hours per batch, which is then given to the individuals for consumption 60 ml three times daily for 21 days. AMBUSH is a herbal preparation in this form but it contains an active ingredient which is a 'NEW' crystalline substance, a drug from the 'palm plant' similarly to ASPIRIN originating from the willow tree bark